BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vieta E, Loft H, Florea I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. European Neuropsychopharmacology 2017;27:877-84. [DOI: 10.1016/j.euroneuro.2017.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Vieta E, Florea I, Schmidt SN, Areberg J, Ettrup A. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2019;34:153-60. [PMID: 31094901 DOI: 10.1097/YIC.0000000000000271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
2 Chokka P, Tvistholm AH, Bougie J, Clerzius G, Ettrup A. Improvements in Workplace Productivity in Working Patients With Major Depressive Disorder: Results From the AtWoRC Study. J Occup Environ Med 2020;62:e94-e101. [PMID: 31895735 DOI: 10.1097/JOM.0000000000001805] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Lachaine J, Beauchemin C, Bibeau J, Patenaude J, Chokka P, Proulx J, Bougie J. Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine. CNS Spectr 2020;25:372-9. [PMID: 31120009 DOI: 10.1017/S1092852919000853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr 2019;24:616-27. [PMID: 30802419 DOI: 10.1017/S1092852919000786] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
5 Gorwood P, Benichou J, Moore N, Wattez M, Secouard MC, Desobry X, Picarel-Blanchot F, de Bodinat C. Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France. Clin Drug Investig 2020;40:1009-20. [PMID: 32729068 DOI: 10.1007/s40261-020-00957-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Vieta E, Arango C, Rush AJ. The need for paediatric registries to assess long-term brain effects of psychotropic medications: The case of bipolar disorder. Eur Neuropsychopharmacol 2018;28:1181-4. [PMID: 30193832 DOI: 10.1016/j.euroneuro.2018.07.104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
7 Vieta E, Earley WR, Burgess MV, Durgam S, Chen C, Zhong Y, Barabássy Á, Németh G. Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder. Int Clin Psychopharmacol 2019;34:76-83. [PMID: 30531358 DOI: 10.1097/YIC.0000000000000246] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Jacobsen P, Zhong W, Xu R, Nomikos G. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study. J Affect Disord 2020;266:173-81. [PMID: 32056873 DOI: 10.1016/j.jad.2020.01.090] [Reference Citation Analysis]
9 Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
10 Biederman J, Lindsten A, Sluth LB, Petersen ML, Ettrup A, Eriksen HF, Fava M. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol 2019;33:511-21. [PMID: 30843450 DOI: 10.1177/0269881119832538] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
11 Atsou K, Ereshefsky L, Brignone M, Danchenko N, Diamand F, Mucha L, Touya M, Becker R, François C. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant. Expert Rev Pharmacoecon Outcomes Res 2021;21:29-42. [PMID: 33307885 DOI: 10.1080/14737167.2021.1855979] [Reference Citation Analysis]
12 Chokka P, Ge H, Bougie J, Ettrup A, Clerzius G. Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study. Ther Adv Psychopharmacol 2021;11:20451253211013148. [PMID: 34025982 DOI: 10.1177/20451253211013148] [Reference Citation Analysis]